Evaluating the potential health and economic impact of different vaccination strategies with the adult-specific 21-valent pneumococcal conjugate vaccine in adults aged ≥ 65 years in Japan

BACKGROUND: We estimated the health and economic impact of adult pneumococcal vaccination strategies in Japan, comparing the adult-specific PCV21 (aPCV21) to PCV20. RESEARCH DESIGN AND METHODS: A published Markov model simulated the epidemiology of pneumococcal disease in Japanese adults aged ≥ 65 years over a lifetime horizon using single- and multi-cohort analyses. Outcomes included cases of invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), disease-related deaths, and direct and indirect costs (2023 Japanese yen [¥]). The base case evaluated vaccination at age 65, while scenario analyses assessed expanded age-based (≥65) vaccination, coverage rates, duration of protection, and indirect protection. RESULTS: Compared to PCV20, aPCV21 prevented 35% more IPD outcomes (cases and deaths) and 33% more NBPP outcomes in the base case. Combined direct and indirect disease/death-related cost savings versus no vaccination increased from ¥3,983 million with PCV20 to ¥5,299 million with aPCV21. Expanding age-based vaccination from adults aged 65 to ≥65 years, prevented an additional 12% points of IPD outcomes and 6% points of NBPP outcomes. Across all scenario analyses, aPCV21 prevented ≥ 25% more cases and costs compared to PCV20. CONCLUSIONS: Based on scenario analyses, the use of aPCV21 in Japanese adults provides substantial health and economic benefits compared to PCV20.

Authors

Institutions

Publication Details

Journal
Expert Review of Vaccines
Published
2026-11-16
DOI
https://doi.org/10.1080/14760584.2026.2761707
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluating the potential health and economic impact of different vaccination strategies with the adult-specific 21-valent pneumococcal conjugate vaccine in adults aged ≥ 65 years in Japan

Kelly D. Johnson, Atsushi Tajima, Zinan Yi, Peter P. Mueller et al.
Expert Review of Vaccines
Pneumonia and Respiratory Infections
article

Evaluating the potential health and economic impact of different vaccination strategies with the adult-specific 21-valent pneumococcal conjugate vaccine in adults aged ≥ 65 years in Japan

Kelly D. Johnson, Atsushi Tajima, Zinan Yi, Peter P. Mueller, Taizo Matsuki, Nicole Cossrow, Kelsie Cassell, Kwame Owusu‐Edusei
article en

Abstract

BACKGROUND: We estimated the health and economic impact of adult pneumococcal vaccination strategies in Japan, comparing the adult-specific PCV21 (aPCV21) to PCV20. RESEARCH DESIGN AND METHODS: A published Markov model simulated the epidemiology of pneumococcal disease in Japanese adults aged ≥ 65 years over a lifetime horizon using single- and multi-cohort analyses. Outcomes included cases of invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), disease-related deaths, and direct and indirect costs (2023 Japanese yen [¥]). The base case evaluated vaccination at age 65, while scenario analyses assessed expanded age-based (≥65) vaccination, coverage rates, duration of protection, and indirect protection. RESULTS: Compared to PCV20, aPCV21 prevented 35% more IPD outcomes (cases and deaths) and 33% more NBPP outcomes in the base case. Combined direct and indirect disease/death-related cost savings versus no vaccination increased from ¥3,983 million with PCV20 to ¥5,299 million with aPCV21. Expanding age-based vaccination from adults aged 65 to ≥65 years, prevented an additional 12% points of IPD outcomes and 6% points of NBPP outcomes. Across all scenario analyses, aPCV21 prevented ≥ 25% more cases and costs compared to PCV20. CONCLUSIONS: Based on scenario analyses, the use of aPCV21 in Japanese adults provides substantial health and economic benefits compared to PCV20.

Expert Review of VaccinesVol. 25(1)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), MSD K.K. (Japan) (JP)
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon